SCHEMBL1167480

SCHEMBL1167480

CC(C)(C)Oc1ccc(C(=O)n2nc(Nc3ccc(N4CCCC4)cc3)nc2N)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INSR P06213 1/20 0.53
AXL P30530 1/20 0.53
JAK1 P23458 4/20 0.47
TYK2 P29597 4/20 0.47
CCNB2 O95067 2/20 0.47
CDK1 P06493 2/20 0.47
CCNB1 P14635 2/20 0.47
CCNB3 Q8WWL7 2/20 0.47
JAK2 O60674 3/20 0.45
JAK3 P52333 3/20 0.45
F12 P00748 2/20 0.43
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
NR4A1 P22736 2/20 0.42
KMT2A Q03164 2/20 0.42
RAB9A P51151 1/20 0.42
MCL1 Q07820 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1167656 0.93 F12 (0.53) INSRAXLJAK1TYK2CCNB2
SCHEMBL1167667 0.93 AXL (0.57) INSRAXLJAK1TYK2CCNB2
SCHEMBL1167659 0.87 INSR (0.53) INSRAXLJAK1TYK2CCNB2
SCHEMBL1168104 0.86 MAPT (0.58) INSRAXLJAK1TYK2CCNB2
SCHEMBL1167539 0.86 INSR (0.55) INSRAXLJAK1TYK2CCNB2
SCHEMBL1167486 0.86 MAPT (0.59) INSRAXLJAK1TYK2CCNB2
SCHEMBL1167428 0.85 AXL (0.56) INSRAXLJAK1TYK2JAK2
SCHEMBL1167754 0.85 CCNB2 (0.58) JAK1TYK2CCNB2CDK1CCNB1
SCHEMBL1167909 0.85 MAPT (0.42) INSRAXLCCNB2CDK1CCNB1
SCHEMBL1167340 0.84 BACE1 (0.56) INSRAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2007-09-13 US claimed
US-8389557-B2 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2013-03-05 US disclosed
US-20110082131-A1 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-7884119-B2 protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation RIGEL PHARMACEUTICALS, INC. (US) 2011-02-08 US disclosed
EP-1922310-A2 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2008-05-21 EP disclosed
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2007-09-13 US disclosed
WO-2007030680-A2 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082131-A1 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS AXL, TYRO3, FLT3 INSR 508/4885AXL 1/4885JAK1 99/4885
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors AXL, TYRO3, FLT3 INSR 291/4885AXL 1/4885JAK1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.